Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies.

Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies.

Item
http://www.wikidata.org/entity/Q37221480
Lipid Nanoparticles for Ocular Gene DeliveryDexamethasone-(C21-phosphoramide)-[anti-EGFR]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency against pulmonary adenocarcinoma (A549)Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomasAlbumin-based nanoparticles as methylprednisolone carriers for targeted delivery towards the neonatal Fc receptor in glomerular podocytesChronic lymphocytic leukaemia--the role of the microenvironment pathogenesis and therapy.Targeted liposomal drug delivery systems for the treatment of B cell malignancies.In pursuit of a moving target: nanotherapeutics for the treatment of non-Hodgkin B-cell lymphoma.The use of nanoparticles as a promising therapeutic approach in cancer immunotherapy.Novel Drug Delivery Systems Tailored for Improved Administration of Glucocorticoids.A novel liposomal formulation of FTY720 (fingolimod) for promising enhanced targeted delivery.CD74 Deficiency Mitigates Systemic Lupus Erythematosus-like Autoimmunity and Pathological Findings in Mice.Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma.Controlled delivery of dexamethasone to the intestine from poly(vinyl alcohol)–poly(acrylic acid) microspheres containing drug-cyclodextrin complexes: influence of method of preparation of inclusion complex
P2860

Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies.

Item
http://www.wikidata.org/entity/Q37221480
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 December 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Milatuzumab-conjugated liposom ...... in CD74+ B-cell malignancies.
@en
Milatuzumab-conjugated liposom ...... in CD74+ B-cell malignancies.
@nl
type
label
Milatuzumab-conjugated liposom ...... in CD74+ B-cell malignancies.
@en
Milatuzumab-conjugated liposom ...... in CD74+ B-cell malignancies.
@nl
prefLabel
Milatuzumab-conjugated liposom ...... in CD74+ B-cell malignancies.
@en
Milatuzumab-conjugated liposom ...... in CD74+ B-cell malignancies.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P698
P921
P932
P356
P1433
P1476
Milatuzumab-conjugated liposom ...... in CD74+ B-cell malignancies.
@en
P2093
P2860
P304
P31
P356
10.1158/1078-0432.CCR-12-2046
P407
P433
P478
P50
P577
P698
P921
P932